Twenty three stable monoclonal antibodies (mAbs) against β " -bungarotoxin (β " -bgt) were prepared by the hybridoma technique. Seven of the 23 mAbs (mAbs 2, 6, 8, 11, 17, 21 and 22) could inhibit more than 70 % of phospholipase A # activity of β " -bgt and neutralize the toxin. Six of these neutralizing mAbs (mAbs 2, 6, 8, 17, 21 and 22) recognized continuous epitopes on the A chain of β " -bgt and the other one (mAb 11) recognized a conformational epitope on the toxin. The continuous epitopes of these six mAbs were mapped using synthetic peptide and proteolytic enzymes. Experimental results indicate that mAb 17 recognized the A-chain residues 31-37 ; mAbs 2 and 8 recognized residues 46-51 ; mAbs 21 and 22 recognized residues 91-98 ; and
INTRODUCTION
β-Bungarotoxin (β-bgt), isolated from the venom of Bungarus multicinctus (the Taiwan banded krait) [1] [2] [3] [4] , is one of the most investigated presynaptic neurotoxins from snake venom. β-Bgt contains covalently linked A and B chains. There are three Achain isoforms (A-1, A-2 and A-3) and two B-chain isoforms (B-1 and B-2) which combine to form five isotoxins (β " -β & ) [3] ; a sixth isotoxin has also been purified [5] . Another novel A-chain cDNA has also been cloned by Chang et al. [6] . β " -Bgt is the main and the most toxic isoform (with a mouse LD &! of 19 µg\kg of body weight) in the β-bgt family [2, 3] . The toxin consists of two dissimilar polypeptide chains : the A-1 chain with 120 amino acid residues (13.5 kDa) and the B-1 chain with 60 amino acid residues (7 kDa), crosslinked by an interchain disulphide bond [3] and possesses weak phospholipase A # (PLA # ) activity [7] . The amino acid sequence of the A chain is homologous with those of PLA # enzymes from snake venoms and the mammalian pancreas, whereas the B chain serves as a recognition subunit of the toxin to a specific target cell membrane and blocks the potassium channel [8] .
Recently, Kwong et al. [9] proposed the detailed mechanism of β-bgt action from their studies on the crystal structure of β # -bgt. The enzymic and pharmacological properties of β " -bgt have been reported and its structure-function relationship has also been studied [3, 10] . However, only two studies on the immunological properties of β " -bgt have been described. Strong et al. [11] and Danse and Kempf [12] used modified β-bgt to immunize animals, however, these modifications could not reduce the toxin's toxicity and enzymatic activity.
In this study, seven β " -bgt-neutralizing monoclonal antibodies (mAbs) were prepared and the protective effect on the toxin in i o was investigated. By using synthetic peptides and proteolysis of β " -bgt, we were able to locate the neutralizing mAbs contact sites on the β " -bgt molecule. Furthermore, according to the Abbreviations used : β 1 -bgt, β 1 -bungarotoxin ; KLH, keyhole-limpet haemocyanin ; mAb, monoclonal antibody ; PLA 2 , phospholipase A 2 ; HAT, hypoxanthine/aminopterin/thymidine ; HT, hypoxanthine/thymidine ; PEG, polyethyleneglycol ; sulfo-MBS, m-maleimidobenzoyl-N-hydroxysulphosuccinimide ester. 1 To whom correspondence should be addressed.
mAb 6 recognized residue 100-106. The competitive-antibodybinding inhibition experiments showed that the affinity of these neutralizing mAbs to the native β " -bgt is compatible with synthetic peptides. Furthermore, mice immunized with BSAconjugated A-chain-peptide sequences A(31-37), A(46-51), A(91-98) or A(100-106) were protected from a high-dose β " -bgt challenge. Subsequently, the peptide-immunized sera were passively injected into Balb\c mice and a significantly protective effect was also observed. To our knowledge, this study is the first systematic demonstration of multiple neutralizing B-cell epitopes of β " -bgt, and this study is also the first report of the protective synthetic-peptide vaccine against β " -bgt challenge.
epitope-mapping results, four peptide fragments that could potentially protect mice from a high dose of toxin challenge have proved to be candidates for a synthetic peptide vaccine.
EXPERIMENTAL Materials
β-Bgt and its isotoxins from B. multicinctus venom were isolated as previously described [13, 14] , and further purified by reversedphase HPLC on a SynChropak RP-P column (4.6 mmi25 cm ; SynChrom, Lafayette, IN, U.S.A.). The purity was verified by PAGE. Dithiothreitol, SDS, BSA, 2,6,10,14-tetramethylpentadecane (pristane), Dulbecco's modified Eagle's medium and acid protease A were purchased from the Sigma Chemical Co., St Louis, MO, U.S.A. Nitro Blue Tetrazolium, 5-bromo-4-chloro-3-indolyl phosphate and anti-mouse IgG (heavy and light) alkaline phosphatase conjugated were obtained from Promega, Madison, WI, U.S.A. Hypoxanthine\aminopterin\thymidine (HAT) and hypoxanthine\thymidine (HT) selection media, polyethyleneglycol (PEG) 4000 and peroxidase-conjugated goat anti-mouse IgG (HjL) were purchased from Boehringer Mannheim GmbH, Mannheim, Germany. Keyhole-limpet haemocyanin (KLH), m-maleimidobenzoyl-N-hydroxysulphosuccinimide ester (sulfo-MBS), glutaraldehyde and micro BCA protein assay kit were purchased from Pierce, Rockford, IL, U.S.A. Immuno-precipitin (formalin-fixed Staphylococcus aureus cells) was purchased from Gibco BRL, Gaithersburg, MD, U.S.A. Thermolysin and pepsin were purchased from Worthington Biochemical Corporation, NJ, U.S.A. All other reagents were of analytical grade.
Preparation of β 1 -bgt mAbs
mAbs were produced essentially according to the method described by Ko$ hler and Milstein [15] with some modification.
Balb\c mice were immunized with increasing doses of β " -bgt (0.1-15 µg\mouse) over a period of 10 weeks. An additional boost (20 µg\mouse) was injected 3 days before fusion. Spleen cells (3i10() were fused with myeloma cells NS-1 (1i10() using PEG 4000. After removal of PEG 4000, cells were suspended in a HAT selection medium and cultured with HAT and HT selection media until myeloma cells disappeared. Hybrid-containing wells were tested by an enzyme immunosorbent assay and positive clones were subcloned by limiting dilution. Hybridoma cells (2.5i10') producing mAbs were injected intraperitoneally into pristane-primed Balb\c mice. Ascites fluids were withdrawn and the mAbs were precipitated by 50 % saturated (NH % ) # SO % and purified through a column of high-performance Protein G (10 mmi10 cm). The purity of the mAbs was verified by SDS\ PAGE and their subclasses were determined by enzyme immunoassay using the Mouse MonoAb-ID Kit (Zymed Laboratories Inc., CA, U.S.A.).
Dot blotting of denatured β 1 -bgt
Dot blotting of denatured β " -bgt was performed, essentially according to the method described by Hawkes [16] with some modifications. Denatured β " -bgt (100 µg\ml in 0.1 M phosphate buffer (pH 7.6) containing 6 M guanidine hydrochloride) on a 1 cm# Immobilon-P PVDF membrane (Millipore Corp., Bedford, MA, U.S.A.) were incubated with a primary antibody solution (i1000) containing 5 % non-fat milk at 37 mC for 2 h. The filter was washed three times each in PBS\Tween 20 and PBS, and incubated with a secondary antibody solution, alkaline phosphatase-conjugated goat anti-mouse IgG (i5000) containing 5 % non-fat milk, at 37 mC for 2 h. After rinsing the filter in a substrate buffer (100 mM Tris\100 mM NaCl\5 mM MgCl # , pH 9.5), one drop of substrate solution containing 6.6 µl of Nitro Blue Tetrazolium and 3.3 µl of 5-bromo-4-chloro-3-indolyl phosphate were added. The blot was developed at room temperature with agitation until the band became purple, and was then rinsed with PBS containing 20 mM EDTA to stop the reaction.
Hydrolysis of the A chain of β 1 -bgt with proteolytic enzymes
Reduced and S-carboxymethylated A chain of β " -bgt (1 mg) was dissolved in : (i) 300 µl of 50 mM ammonium bicarbonate buffer at pH 7.8, and thermolysin was added to give a protein : enzyme ratio of 50 : 1 (w\w) ; (ii) 250 µl of 5% acetic acid (pH 2.0), and acid protease was added (in a ratio of 30 : 1, w\w) ; and (iii) 250 µl of 10 mM HCl (pH 2.0) and pepsin was added (in a ratio of 50 : 1, w\w). Digestion was performed at 37 mC for 3 h and the hydrolysate was filtered through a 0.22 µm filter and lyophilized. The lyophilized hydrolysates were separated on a SynChropak RP-18 column (4.6 mmi25 cm) equilibrated with 0.1 % trifluoroacetic acid and eluted by a linear gradient of 0-40 % acetonitrile for 40 min. Peptide fragments were collected and lyophilized for ELISA [17] and amino acid analysis.
Peptide conjugation to carrier protein
All of the synthetic peptides were synthesized from Chiron, Victoria, Australia. The molecular mass of synthetic peptides was confirmed by electrospray-ionization MS ; all of them were of purity exceeding 85 %. Glutaraldehyde coupling [18] and sulfo-MBS coupling [19] were used for conjugating synthetic peptide to carrier protein. For synthetic peptides bound covalently via amine groups to the carrier protein, 0.75 mg of peptide in 100 mM sodium phosphate buffer (pH 8.0) was mixed with 0.75 mg of carrier protein, and made up to 100 µl with buffer. Subsequently, 2 µl of 25% glutaraldehyde was added to the reaction mixture and left for 20 min at room temperature. Then, 2 µl of 15% glutaraldehyde was added and left for another 15 min. Finally, 20 µl of 1 M glycine buffer (pH 6.0) was added to quench the glutaraldehyde. The conjugate for immunization was dialysed against PBS to remove free peptide. For synthetic peptides bound covalently via sulphydryl groups to the carrier protein, 0.1 mg of sulfo-MBS was mixed with 1 mg of BSA in 150 µl of conjugation buffer (0.083 M sodium phosphate\0.9 M NaCl\0.1 M EDTA, pH 7.2) and incubated at room temperature for 1 h. After dialysing the mixture with conjugation buffer, 1 mg of synthetic peptide was added to the mixture. The mixture was incubated at room temperature for another 2 h and the conjugate was dialysed against PBS to remove free peptide.
Immunization of mice with BSA-peptide conjugate
Each BSA-peptide conjugate (100 µg) was emulsified in Freund's complete adjuvant and injected intramuscularly into a Balb\c mouse. Subsequently, five doses of booster injection with 1 mg of BSA-peptide conjugate emulsified in Freund's incomplete adjuvant were administered at weekly intervals. The titre of antipeptide antibody in serum was determined by ELISA that was coated with 100 µl of KLH-peptide conjugate (1 µg\ml).
Affinity chromatography of peptide-specific antibody preparation on KLH-peptide-Sepharose
Covalent coupling of KLH-peptide to CNBr-activated Sepharose 4B was carried out according to the method described by Yang et al. [20] . An aliquot of the KLH-peptide-Sepharose was poured into a column (10 mmi10 cm) and equilibrated with PBS. The (NH % ) # SO % -purified antibody solutions against BSApeptide were applied by passage through the column of KLHpeptide-Sepharose. The column was washed with 100 ml of PBS and 80 ml of 0.1 M acetate buffer\0.5 M NaCl (pH 4.0). The peptide-specific antibodies were then eluted with 0.53 M formic acid\0.15 M NaCl (pH 2.05) ; the effluent was neutralized immediately with 1.0 M glycine\NaOH buffer (pH 12.0). The antibody preparations were dialysed against PBS and concentrated in a visking tube under a vacuum.
Other tests
Determinations of PLA # activity, lethal toxicity, PAGE, amino acid analysis and sequence determination, and immunoblot analysis were performed in essentially the same manner as previously described [21, 22] .
RESULTS

Characterization of β 1 -bgt mAbs
Twenty three stable hybridoma lines were generated in an experiment in which 960 wells were plated, of which 455 contained colonies and 51 showed significant β " -bgt-binding activity. mAbs produced by 23 stable hybridoma cell lines were incubated with subclass-specific goat anti-mouse Ab in an ELISA plate for isotyping. Nineteen out of the 23 mAbs were sub-isotyped as IgG2b, while the others were IgG1. The specificity of these hybridoma lines was also tested by ELISA and immunoprecipitation against β " -bgt ; the results indicated that these mAbs could specifically bind to β " -bgt. Affinity constants of these mAbs were measured by the solid-phase ELISA titration method and ranged from 10'-10"! l\mol (results not shown).
Inhibition of enzymic activity was performed in itro with the same molar ratio of antibody that was preincubated with 3 µg of β " -bgt in 100 µl of PBS at 37 mC for 3 h. A non-specific mouse * Affinity was determined according to the method described by Friguet et al. [28] . † Inhibition of enzymic activity was performed in vitro with the same molar ratio of antibody that was preincubated with 3 µg of β 1 -bgt in 100 µl of PBS at 37 mC for 3 h. A non-specific mouse anti-human IgG1 was used as a control.
‡ The LD 50 and the neutralizing capacity were calculated according to the method described by Yang and King [21] . § The j and k signs mean the positive and negative results in dot blotting, respectively. The positive signal indicates that the epitope of corresponding mAb is the continuous form. In contrast, the negative signal indicates the mAb corresponding epitope is conformation-dependent.
Figure 1 Immunoblotting analysis of the A and B chains of β 1 -bgt recognized by β 1 -bgt mAbs
Lanes 1 and 2, SDS-PAGE of intact β 1 -bgt and β 1 -bgt treated with β-mercaptoethanol, respectively. Six odd lanes (3-13), and six even lanes (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , are intact β 1 -bgt and β 1 -bgt treated with β-mercaptoethanol, respectively. They were resolved by SDS/PAGE, transferred to a PVDF membrane and probed with mAbs 2, 6, 8, 17, 21 and 22, respectively.
anti-human IgG1 was used as a control. Seven out of 23 mAbs (mAbs 2, 6, 8, 11, 17, 21 and 22) could inhibit more than 70 % of the PLA # activity of β " -bgt (Table 1) . The potential toxic neutralizing activity of these 23 mAbs was tested on mice with various amounts of antibodies which had been preincubated with three times the LD &! dose of β " -bgt (the LD &! is 19 µg\kg of body weight). As shown on Table 1 , mAbs 2, 6, 8, 11, 17, 21 and 22 could neutralize toxicity of β " -bgt in i o, the neutralizing capacities of mAb 2 and mAb 8 were particularly high. β " -Bgt was denatured by guanidium hydrochloride and immobilized on PVDF membrane, then hybridized with the seven neutralizing mAbs for dot blotting. Six of these mAbs (mAbs 2, 6, 8, 17, 21 and 22) revealing a positive signal on dot blotting implies that they recognize continuous epitopes, whereas mAb 11 recognizing only the non-reduced antigen implies that the mAb 11 recognized the conformational epitope (Table 1) .
Immunoblotting analysis of the neutralizing mAbs revealed that all the six mAbs bound to the A chain (13.5 kDa) as well as to the intact β " -bgt (20.5 kDa) (Figure 1 ). No evidence suggested that any blot corresponded to the B chain (7 kDa). The control experiments using Amido-Schwarz staining demonstrated that both A and B chains were equally transferred to the PVDF membrane under the blotting conditions used.
Epitope mapping of β 1 -bgt with synthetic peptides and proteolysis methods
Continuous epitopes for six neutralizing mAbs binding to β " -bgt were studied by using synthetic peptides and proteolysis methods. Selecting the possible antigenic peptide epitopes contained in the A (91-98) . The other two neutralizing mAbs 6 and 17 did not react with any of the four synthetic peptides. For the sake of fine-mapping the epitopes of mAbs 2 and 8, another four peptides (Table 2 ; A(46-51), A(46-53), A(52-61) and A(54-61) were synthesized. By direct ELISA test, mAbs 2 and 8 reacted with A(44-64), A(46-51) and A(46-53) peptides, indicating that both mAbs 2 and 8 recognized the amino acid sequence 46-51 of the A chain. The direct ELISA also revealed that the binding ability of these β " -bgt mAbs to BSA-peptide conjugates was in a dose-dependent manner ( Figure  3) .
To determine the continuous epitopes of neutralizing mAbs 6 and 17, thermolysin, acid protease A and pepsin were sequentially used to hydrolyse the A chain of β " -bgt and the peptide fragments were separated by reversed-phase HPLC on a column of SynChropak RP-P (Figure 4 ). The peptide fragments were conjugated with BSA by glutaraldehyde and the immunoreactivity of mAbs against these fragments was determined by direct ELISA. According to Figure 4 , fragments T-1, A-1 and A-2 reacted with mAb 17. On the other hand, fragments P-1, P-2 and P-3 reacted with mAb 6. Table 3 lists the amino acid compositions of these proteolytic fragments and their location on the amino acid sequence of the A chain of β " -bgt is shown in Figure 5 (a). According to these results, the epitopes of mAbs 6 and 17 were within the sequences 100-106 and 31-37, respectively.
All of the continuous epitopes of neutralizing mAbs have been determined by synthetic peptides or by the proteolysis method. The competitive antibody-binding inhibition experiments showed that the binding activity of these neutralizing mAbs to native β " -bgt is compatible with the corresponding synthetic peptides (Figure 6 ), suggesting that synthetic peptides can form structures comparable with the neutralizing epitopes on β " -bgt. Figure 5 (b) summarizes the mapped neutralizing B-cell epitopes.
Protective capacity of peptide-immunized mice
Peptides A(31-37), A(46-51), A(91-98) and A(100-106) containing the neutralizing epitopes of the toxin identified with β " -bgt mAbs were synthesized and coupled to the carrier protein (BSA). They were injected intramuscularly into Balb\c mice with Freund's complete adjuvant and then with Freund's incomplete adjuvant. The peptide-specific antibodies in the sera of mice were detected by ELISA at weekly intervals. As Figure 7 reveals, the titre of specific antibodies went up to a maximum about 4 weeks after the first immunization. Table 4 compares the survival ratios of peptide-immunized mice that were challenged with 10iLD
These results indicate that all of these synthetic peptides, A(31-37), A(46-51), A(91-98) and A(100-106), had the capacity to protect mice from β " -bgt challenge, yet mice immunized with synthetic peptides A(46-51) and A(100-106) were more protected than those with A(31-37) and A(91-98). IgG and peptide-specific antibody purified from immunized sera also preserved the capacity to inhibit PLA # activity and toxicity of β " -bgt (Table 4 ). In contrast, the scramble peptide (MVRVFPNVYVYSNIYIY-PNIGIAF) or BSA-control-immunized mice had undetectable protective activity. † To conjugate the peptide to the carrier protein (BSA), the cysteine residue was added to the N-terminal end of the synthetic peptide to offer a free thiol group to the conjugating linker (sulfo-MBS).
Figure 3 Direct ELISA displaying the binding ability of β 1 -bgt mAbs to BSA-peptide conjugates
ELISA was performed essentially according to the method described by Tanaka et al. [17] . 100 µl of BSA or BSA-peptide conjugates (1 µg/ml) were coated on to the ELISA plate and different concentrations of 
Reduction of mortality by passively transferred anti-peptide sera or peptide-specific antibodies
To test whether anti-peptide-immunized sera could produce protective immunity against β " -bgt in mice, a passive transfer experiment was performed. Donor mice were immunized with BSA-conjugated peptides A(31-37), A(46-51), A(91-98), A(100-106) and scramble peptide. Sera were collected 3 days after the last booster injection and pooled. Control serum was obtained from mice immunized with BSA alone. The undiluted pooled sera (0.5 ml), peptide-specific antibodies (0.25, 0.5 or
Figure 4 Separation of the peptide fragments of the A chain of β 1 -bgt after hydrolysis with thermolysin (A), acid protease A (B) and pepsin (C)
0.1 mg of proteolytic hydrolysate was applied to a SynChropak RP-P column (4.6 mmi25 cm) equilibrated with 0.1 % trifluoroacetic acid and eluted with a linear gradient of 0-40 % acetonitrile for 40 min. The flow rate was 0.8 ml/min and the effluent was monitored at 235 nm.
Table 3 Amino acid composition of peptides obtained from digestion of A chain of β 1 -bgt with thermolysin, acid protease A and pepsin
Numbers in brackets denote the calculated number of amino acid residues in peptide.
Thermolysin Acid protease A Pepsin 1 mg) or immunoglobulin-free serum were injected intravenously into male Balb\c mice. After 12 h, the recipient mice were challenged with 5iLD &! of β " -bgt. According to these results, all of the peptide-immunized sera had the ability to protect passively transferred mice from toxin challenge to varying degrees (Table  5) . Furthermore, mice injected with peptide-specific antibody purified from anti-peptide sera had a distinct protective effect against toxin challenge in a dose-dependent manner. In contrast, all of the immunoglobulin-free sera fractions had no protective effect. 
DISCUSSION
Both polyclonal and monoclonal antibodies are considered highly effective tools in examining protein structure and function. Therefore, in this study, β " -bgt mAbs are prepared for the study of the structure and function of β " -bgt and related toxins. Immunization of animals is critical in preparing mAbs, particularly for the low-LD &! toxin, β " -bgt, because a high dose of toxin antigen may kill the animal and a low dose of antigen may induce a weak immune response. To prevent these problems, animals were immunized by a low dose of toxin with a high immunization number. After 73 days immunization, all Balb\c mice reached a highly immunized state and the titre of β " -bgt Ab in blood was high.
By means of proteolytic hydrolysis and synthetic peptide methods, six continuous neutralizing epitopes have been mapped on to four distinct regions in a sequence of the toxin. The shortest epitopes appear to be six amino acid residues and the longest eight. The hydropathy plot analysis [23] (Figure 2A ) revealed that the epitopes for mAbs 17, 21 and 22 are located in hydrophilic regions, epitopes for mAbs 2 and 8 are in an intermediate region, but the epitope of mAb 6 is located in a hydrophobic region. On the other hand, the antigenic index profile [24] (Figure 2B ) predicted that the epitopes of mAbs 21 and 22 are high in antigenicity, epitopes of mAbs 2 and 8 are intermediate, and epitopes of mAbs 6 and 17 are low in antigenicity. The chain flexibility profiles [25] (Figure 2C ) revealed that the epitopes of mAbs 2, 8, 17, 21 and 22 are located on intermediate flexibility regions ; however, the epitope of mAb 6 is located on a low flexibility region. From these predictions, the epitope of mAb 6 is located in a region predicated to be hydrophobic, rigid and inaccessible, indicating that the region is unfavourable for antigenicity. The fact that the antibody binding was demonstrated in itro with native protein (in ELISA) clearly indicates that this epitope could not be masked in a protein molecule.
The epitope of mAbs 2 and 8 was located at the sequence 46-51 of the A chain of β " -bgt, which contained two essential catalytic residues, His-48 and Asp-49. From a structural perspective, His-48 and Asp-49 are responsible for catalytic activity and constructing the catalytic network ; thus, blocking His-48 and Asp-49 may potentially inhibit enzymic activity and toxicity. From the standpoint of affinity constants, the affinity of mAb 8 is higher than that of mAb 2 ; this may possibly account for the inhibition of enzymic activity and toxicity by mAb 8 being stronger than mAb 2. The experimental results apparently suggest that these two mAbs inhibit the biological activity of β " -bgt, which appears to be consistent with the previous reports [9, 26] . Asp-92 is also an essential catalytic residue located within the epitope of mAbs 21 and 22 ; therefore, the biological activities of β " -bgt might be blocked by these two mAbs. According to bovine pancreatic-PLA # crystal structure, the carbonyl oxygens of Tyr-28, Gly-30 and Gly-32, and the carboxylate oxygens of Asp-49 and two water molecules form an oxygen cage that sequesters a Ca# + ion [27] . From the above observation, we can infer that mAb 17 can block Gly-32, and inhibit the PLA # activity of β " -bgt.
Most neutralizing B-cell epitopes are conformational rather than continuous, even in the case of continuous neutralizing epitopes, and the conformation of synthetic peptides does not consistently maintain a structure identical to the linear epitopes on native β " -bgt protein, thereby limiting the development of an efficient synthetic-peptide vaccine. Therefore, it is important when designing the peptide vaccine to analyze the conformational or continuous neutralizing epitopes and to study the identity of neutralizing epitopes on the synthetic peptide with reference to those on native β " -bgt. Our results indicated that the neutralizing mAbs (mAbs 2, 6, 8, 17, 21 and 22) reacted with their corresponding synthetic-epitope sequences, and the binding of these neutralizing mAbs to β " -bgt was efficiently inhibited by the corresponding synthetic peptides. This finding suggests that these synthetic peptides can form conformations comparable to the neutralizing epitopes on the native β " -bgt and become potential candidates for peptide vaccine.
In this study, peptides A(31-37), A(46-51), A(91-98) and A(100-106) induced antisera which not only revealed the protective capacity in experiments in i o, but also displayed the neutralizing of PLA # activity in experiments in itro (Table 4) . However, passive protection experiments (Table 5 ) with anti-A(31-37), A(46-51), A(91-98) and A(100-106) antisera indicate that antibody purified from immune sera proved to be a major component for protecting mice from toxin challenge. These combined results demonstrated that the protection induced by the peptide is antibody-mediated. On the other hand, T-cell responses also play an essential role in B-cell proliferation and activation. The T-cell epitopes in this vaccination experiment were not localized in the synthetic peptides but within the carrier protein.
